FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Alain Latil

Research Profile

Disorders

Procedures

Chemicals & Drugs

Physiology

Gene Expression Regulation, Neoplastic

Genes & Molecular Sequences

Concepts & Ideas

Neoplasm Staging

Anatomy

Co-author Network

Publications

TOP 3
Francis DUBOSQ; Alain Latil; Hugues de The; François Desgrandchamps; Guillaume Ploussard; Hany Soliman; Elisabeth Turpin; Pierre Mongiat-Artus
Identification of a three-gene expression signature of early recurrence in non-muscle-invasive urothelial cell carcinoma of the bladder.
Alain Latil; Christine Libon; Didier Junquero; Frédérique Lantoine-Adam; Marie Templier; Thien Nguyen
Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro.
Alain Latil; Isabelle Roche
[The mortuary: a place where lives can be saved].

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Alain Latil (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Francis DUBOSQ; Alain Latil; Hugues de The; François Desgrandchamps; Guillaume Ploussard; Hany Soliman; Elisabeth Turpin; Pierre Mongiat-Artus
Identification of a three-gene expression signature of early recurrence in non-muscle-invasive urothelial cell carcinoma of the bladder.
Urologic oncology 2012;30(6):833-40.
2012: Alain Latil; Christine Libon; Didier Junquero; Frédérique Lantoine-Adam; Marie Templier; Thien Nguyen
Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro.
BJU international 2012;110(6 Pt B):E301-7.
2011: Alain Latil; Isabelle Roche
[The mortuary: a place where lives can be saved].
Soins; la revue de référence infirmière 2011;(761):45-6.
2011: François D'Anjou; Sophie Routhier; Jean-Pierre Perreault; Alain Latil; David Bonnel; Isabelle Fournier; michel salzet; Robert Day
Molecular Validation of PACE4 as a Target in Prostate Cancer.
Translational oncology 2011;4(3):157-72.
2005: Gaëlle Fromont; Antoine Valeri; Michael L Cher; J Edson Pontes; Guy Vallancien; Pierre Validire; Alain Latil; Olivier Cussenot
Allelic loss at 16q23.2 is associated with good prognosis in high grade prostate cancer.
The Prostate 2005;65(4):341-6.
2005: Gaëlle Fromont; Laurent Chene; Michel Vidaud; Guy Vallancien; Philippe Mangin; Georges Fournier; Pierre Validire; Alain Latil; Olivier Cussenot
Differential expression of 37 selected genes in hormone-refractory prostate cancer using quantitative taqman real-time RT-PCR.
International journal of cancer. Journal international du cancer 2005;114(2):174-81.
2005: Antoine Valeri; Gaëlle Fromont; Wael A Sakr; Rahmène Azzouzi; Jyotirmoy Dey; Karine Chantrel-Groussard; Alain Latil; Philippe Berthon; Olivier Cussenot; J Edson Pontes; Michael L Cher
High frequency of allelic losses in high-grade prostate cancer is associated with biochemical progression after radical prostatectomy.
Urologic oncology 2005;23(2):87-92.
2005: R Thuret; Karine Chantrel-Groussard; Abdel-Rahmène Azzouzi; Jean-Marie Villette; S Guimard; Pierre Teillac; Philippe Berthon; Alain Houlgatte; Alain Latil; Olivier Cussenot
Clinical relevance of genetic instability in prostatic cells obtained by prostatic massage in early prostate cancer.
British journal of cancer 2005;92(2):236-40.
2004: Gaëlle Fromont; Laurent Chene; Alain Latil; Ivan Bieche; Michel Vidaud; Guy Vallancien; Philippe Mangin; Georges Fournier; Pierre Validire; Olivier Cussenot
Molecular profiling of benign prostatic hyperplasia using a large scale real-time reverse transcriptase-polymerase chain reaction approach.
The Journal of urology 2004;172(4 Pt 1):1382-5.
2004: Laurent Chêne; Christiane Giroud; François Desgrandchamps; Laurent Boccon-Gibod; Olivier Cussenot; Philippe Berthon; Alain Latil
Extensive analysis of the 7q31 region in human prostate tumors supports TES as the best candidate tumor suppressor gene.
International journal of cancer. Journal international du cancer 2004;111(5):798-804.
2004: Najla Amira; Géraldine Cancel-Tassin; Stéphane Bernardini; Béatrix Cochand-Priollet; Hugues Bittard; Philippe Mangin; Georges Fournier; Alain Latil; Olivier Cussenot
Expression in bladder transitional cell carcinoma by real-time quantitative reverse transcription polymerase chain reaction array of 65 genes at the tumor suppressor locus 9q34.1-2: identification of 5 candidates tumor suppressor genes.
International journal of cancer. Journal international du cancer 2004;111(4):539-42.
2003: Alain Latil; Ivan Bièche; Laurent Chêne; Ingrid Laurendeau; Philippe Berthon; Olivier Cussenot; Michel Vidaud
Gene expression profiling in clinically localized prostate cancer: a four-gene expression model predicts clinical behavior.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(15):5477-85.
2003: Gaëlle Fromont; Vincent Joulin; Karine Chantrel-Groussard; Guy Vallancien; Bertrand Guillonneau; Pierre Validire; Alain Latil; Olivier Cussenot
Allelic losses in localized prostate cancer: association with prognostic factors.
The Journal of urology 2003;170(4 Pt 1):1394-7.
2003: Géraldine Cancel-Tassin; Alain Latil; Francis Rousseau; Philippe Mangin; Emmanuel Bottius; Jean-Louis Escary; Philippe Berthon; Olivier Cussenot
Association study of polymorphisms in the human estrogen receptor alpha gene and prostate cancer risk.
European urology 2003;44(4):487-90.
2003: Alain Latil; Laurent Chêne; Philippe Mangin; Georges Fournier; Philippe Berthon; Olivier Cussenot
Extensive analysis of the 13q14 region in human prostate tumors: DNA analysis and quantitative expression of genes lying in the interval of deletion.
The Prostate 2003;57(1):39-50.
2003: Alain Latil; Laurent Chêne; Béatrix Cochant-Priollet; Philippe Mangin; Georges Fournier; Philippe Berthon; Olivier Cussenot
Quantification of expression of netrins, slits and their receptors in human prostate tumors.
International journal of cancer. Journal international du cancer 2003;103(3):306-15.
2002: Abdel-Rahmène Azzouzi; Béatrix Cochand-Priollet; Philippe Mangin; Georges Fournier; Philippe Berthon; Alain Latil; Olivier Cussenot
Impact of constitutional genetic variation in androgen/oestrogen-regulating genes on age-related changes in human prostate.
European journal of endocrinology / European Federation of Endocrine Societies 2002;147(4):479-84.
2002: BENYOUSSEF NAIMI; Alain Latil; Georges Fournier; Philippe Mangin; Olivier Cussenot; Philippe Berthon
Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate.
The Prostate 2002;52(3):245-52.
2002: Alain Latil; Patrice Morant; Georges Fournier; Philippe Mangin; Philippe Berthon; Olivier Cussenot
CHC1-L, a candidate gene for prostate carcinogenesis at 13q14.2, is frequently affected by loss of heterozygosity and underexpressed in human prostate cancer.
International journal of cancer. Journal international du cancer 2002;99(5):689-96.
2002: Ivan Bièche; Alain Latil; Béatrice Parfait; Dominique Vidaud; Ingrid Laurendeau; Rosette Lidereau; Olivier Cussenot; Michel Vidaud
CGA gene (coding for the alpha subunit of glycoprotein hormones) overexpression in ER alpha-positive prostate tumors.
European urology 2002;41(3):335-41.
2001: Alain Latil; R Azzouzi; G S Cancel; E C Guillaume; B Cochan-Priollet; Philippe Berthon; O Cussenot
Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways.
Cancer 2001;92(5):1130-7.
2001: Géraldine Cancel-Tassin; Alain Latil; Antoine Valéri; E Guillaume; Philippe Mangin; Georges Fournier; Philippe Berthon; Olivier Cussenot
No evidence of linkage to HPC20 on chromosome 20q13 in hereditary prostate cancer.
International journal of cancer. Journal international du cancer 2001;93(3):455-6.
2001: Alain Latil; M Guérard; P Berthon; O Cussenot
12p12-13 deletion in prostate tumors and quantitative expression of CDKN1B and ETV6 candidate genes.
Genes, chromosomes & cancer 2001;31(2):199-200.
2001: Alain Latil; I Bièche; Dominique Vidaud; R Lidereau; Philippe Berthon; O Cussenot; M Vidaud
Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays.
Cancer research 2001;61(5):1919-26.
2001: Géraldine Cancel-Tassin; Alain Latil; Antoine Valéri; Philippe Mangin; Georges Fournier; Philippe Berthon; Olivier Cussenot
PCAP is the major known prostate cancer predisposing locus in families from south and west Europe.
European journal of human genetics : EJHG 2001;9(2):135-42.
2000: BENYOUSSEF NAIMI; Alain Latil; Philippe Berthon; O Cussenot
No evidence for fibroblast growth factor receptor 3 (FGFR-3) R248C/S249C mutations in human prostate cancer.
International journal of cancer. Journal international du cancer 2000;87(3):455-6.
2000: Alain Latil; Dominique Vidaud; Antoine Valéri; Georges Fournier; M Vidaud; Rosette Lidereau; Olivier Cussenot; I Biàche
htert expression correlates with MYC over-expression in human prostate cancer.
International journal of cancer. Journal international du cancer 2000;89(2):172-6.
2000: Alain Latil; Ivan Bièche; S Pesche; Antoine Valéri; Georges Fournier; Olivier Cussenot; Rosette Lidereau
VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms.
International journal of cancer. Journal international du cancer 2000;89(2):167-71.
1999: Alain Latil; S Pesche; Antoine Valéri; Georges Fournier; Olivier Cussenot; Rosette Lidereau
Expression and mutational analysis of the MADR2/Smad2 gene in human prostate cancer.
The Prostate 1999;40(4):225-31.
1999: Alain Latil; Ivan Bièche; S Pesche; Alain Volant; A Valèri; Georges Fournier; Olivier Cussenot; Rosette Lidereau
Loss of heterozygosity at chromosome arm 13q and RB1 status in human prostate cancer.
Human pathology 1999;30(7):809-15.
1999: Alain Latil; S Pesche; Antoine Valeri; Olivier Cussenot; Georges Fournier; Rosette Lidereau
Common delta2 and delta8 RB1 variants in human breast and prostate tissues.
International journal of cancer. Journal international du cancer 1999;80(4):632-3.
1998: Ivan Bièche; Alain Latil; Véronique Becette; Rosette Lidereau
Study of FHIT transcripts in normal and malignant breast tissue.
Genes, chromosomes & cancer 1998;23(4):292-9.
1998: S Pesche; Alain Latil; F Muzeau; Olivier Cussenot; Georges Fournier; Michel Longy; C Eng; Rosette Lidereau
PTEN/MMAC1/TEP1 involvement in primary prostate cancers.
Oncogene 1998;16(22):2879-83.
1998: Philippe Berthon; Antoine Valeri; A Cohen-Akenine; E Drelon; Thomas Paiss; Gudrun Wöhr; Alain Latil; P Millasseau; I Mellah; N Cohen; Hélène Blanché; C Bellané-Chantelot; Florence Demenais; Pierre Teillac; Alain Le Duc; Robert De Petriconi; Richard Hautmann; I Chumakov; L Bachner; NJ Maitland; Rosette Lidereau; Walther Vogel; Georges Fournier; Philippe Mangin; Olivier Cussenot
Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43.
American journal of human genetics 1998;62(6):1416-24.
1998: Alain Latil; Ivan Bièche; Georges Fournier; Olivier Cussenot; S Pesche; Rosette Lidereau
Molecular analysis of the FHIT gene in human prostate cancer.
Oncogene 1998;16(14):1863-8.
1997: Alain Latil; O Cussenot; Georges Fournier; R Lidereau
Infrequent allelic imbalance at the major susceptibility HPC1 locus in sporadic prostate tumours.
International journal of cancer. Journal international du cancer 1997;71(6):1118.
1997: Alain Latil; O Cussenot; G Fournier; K Driouch; R Lidereau
Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: identification of three independent regions.
Cancer research 1997;57(6):1058-62.
1997: Ivan Bièche; C Noguès; S Rivoilan; A Khodja; Alain Latil; Rosette Lidereau
Prognostic value of loss of heterozygosity at BRCA2 in human breast carcinoma.
British journal of cancer 1997;76(11):1416-8.
1996: Alain Latil; Georges Fournier; Olivier Cussenot; Rosette Lidereau
Differential chromosome allelic imbalance in the progression of human prostate cancer.
The Journal of urology 1996;156(6):2079-83.
1996: Alain Latil; Olivier Cussenot; Georges Fournier; Rosette Lidereau
The BRCA2 gene is not relevant to sporadic prostate tumours.
International journal of cancer. Journal international du cancer 1996;66(2):282-3.
1995: Alain Latil; Olivier Cussenot; Georges Fournier; J C Baron; Rosette Lidereau
Loss of heterozygosity at 7q31 is a frequent and early event in prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(11):1385-9.
1995: Alain Latil; J C Baron; Olivier Cussenot; Georges Fournier; thierry soussi; L Boccon-Gibod; Alain Le Duc; J Rouëssé; Rosette Lidereau
[Genetic alterations in localized cancers of the prostate: identification of a common region of deletion on the chromosome 18q].
Bulletin du cancer 1995;82(7):589-97.
1995: Georges Fournier; Alain Latil; Yolande Amet; J H Abalain; A Volant; P Mangin; H H Floch; Rosette Lidereau
Gene amplifications in advanced-stage human prostate cancer.
Urological research 1995;22(6):343-7.
1994: Alain Latil; J C Baron; Olivier Cussenot; Georges Fournier; L Boccon-Gibod; Alain Le Duc; Rosette Lidereau
Oncogene amplifications in early-stage human prostate carcinomas.
International journal of cancer. Journal international du cancer 1994;59(5):637-8.
1994: Alain Latil; J C Baron; Olivier Cussenot; Georges Fournier; thierry soussi; L Boccon-Gibod; Alain Le Duc; J Rouëssé; Rosette Lidereau
Genetic alterations in localized prostate cancer: identification of a common region of deletion on chromosome arm 18q.
Genes, chromosomes & cancer 1994;11(2):119-25.
1992: MH Champème; Ivan Bièche; Alain Latil; Kamel Hacène; Rosette Lidereau
[Association studies in cancerology: the example of gene L-myc polymorphism associated with the incidence of pulmonary metastases in breast cancers].
Bulletin du cancer 1992;79(12):1149-57.